Xspray Pharma

• NCT06145217

  Phase 1, Completed, 18 people, 24 Nov 2023

• NCT05439408

  Phase 1, Completed, 110 people, 30 Jun 2022

• Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population-based cohort study

  Grants or research support, 1 Oct 2026

Sources: pubmed.ncbi.nlm.nih.gov